BTL Shines a Light on New Hope Beyond Depression with EXOMIND on Life+Leisure with Bill & Giuliana Rancic

Dr. Michelle Dees Explores a Noninvasive, Non-Drug Treatment Option in an Exclusive WE tv Segment Airing October 15, 2026 at 7:30 AM EST

CHICAGO, IL, UNITED STATES, October 13, 2026 /EINPresswire.com/ — For millions of people living with depression, finding the right path forward can be difficult—and for those who have not found sufficient relief from medication, knowing that other treatment options exist can offer an important source of hope. BTL, a global leader in medical technology, will be featured on Life+Leisure, hosted by Bill and Giuliana Rancic, in a segment airing on WE tv on October 15, 2026 at 7:30 AM EST, exploring EXOMIND^® and the evolving role of noninvasive brain stimulation in the treatment of depression.

The episode features Dr. Michelle Dees, a psychiatrist who discusses the realities of depression, why patients should know they are not alone, and how technologies such as EXOMIND are helping bring established Transcranial Magnetic Stimulation (TMS) science into a modern patient experience.

EXOMIND is an FDA-cleared, noninvasive treatment for major depressive disorder in adults who have not achieved satisfactory improvement from antidepressant medication during their current episode. The treatment uses targeted magnetic pulses to stimulate the dorsolateral prefrontal cortex, an area of the brain involved in mood regulation. It requires no surgery or anesthesia and does not introduce medication into the body.

During the segment, Dr. Dees helps demystify what TMS treatment actually looks and feels like for patients. Individuals remain awake during treatment and may experience a tapping sensation as magnetic pulses are delivered through an applicator positioned against the head. Sessions are performed on an outpatient basis, and patients can generally return to their normal activities afterward.

The conversation also explores neuroplasticity—the brain’s ability to strengthen, reorganize and form new neural connections over time—and how repeated stimulation is intended to influence activity within brain networks associated with depression.

Just as importantly, the feature addresses the stigma that can still prevent people from speaking openly about their mental health or seeking additional care. Depression can affect people from every background and stage of life, including those who may appear successful, engaged and high-functioning to those around them.

“The most important message is that people struggling with depression should know they are not alone and that there may be options they haven’t explored yet,” said Bill and Giuliana Rancic. “Conversations like this can help people feel more comfortable asking questions and speaking with their healthcare providers about what might be right for them.”

Dr. Dees also explains that EXOMIND does not necessarily require patients to choose between TMS, medication and talk therapy. Depending on the individual and the guidance of a qualified clinician, TMS may be incorporated into a broader treatment plan or considered as an option for appropriate patients who have not experienced sufficient improvement with medication.

For BTL, EXOMIND represents part of a much broader commitment to developing technologies that help people not only look better, but also feel and function better. Founded in the Czech Republic in 1993, BTL has grown into a global medical device company spanning cardiology, physiotherapy, aesthetics, wellness and other medical specialties. Today, its technologies are distributed in 95 countries, supported by more than 600 research and development professionals working across disciplines.

As a privately held company, BTL has focused on long-term investment in medical innovation, including an increased emphasis on wellness, longevity and healthspan. EXOMIND reflects that evolving mission by addressing mental well-being as an important component of how well people live.

Ultimately, the segment delivers a message of possibility: depression can feel isolating, but patients do not have to suffer silently, and treatment options continue to evolve.

Tune in to WE tv on October 15, 2026 at 7:30 AM EST to watch the full Life+Leisure segment and learn how BTL and EXOMIND are helping expand the conversation around depression, mental well-being and noninvasive treatment options.

About BTL
Founded in 1993, BTL is a global leader in medical device innovation, developing advanced, noninvasive technologies across aesthetics, dermatology, rehabilitation, orthopaedics, dentistry, women’s health, primary care and other medical specialties. With more than 200 patents, over 600 in-house engineers and technologies distributed across 95 countries, BTL combines science and engineering to develop solutions designed to help people look, feel and function better while supporting wellness, longevity and quality of life.

Depression Sucks. Life Shouldn’t. Strengthen Your Mind with EXOMIND.
Learn more at www.btlhealthcare.com.

About Life+Leisure
Life+Leisure, hosted by Bill and Giuliana Rancic, is a dynamic lifestyle series exploring the intersections of wellness, health, travel, design and innovation. Airing on WE tv and Bloomberg International, the show inspires audiences to elevate everyday living through expert insights, innovative solutions and real stories of empowerment. Learn more at www.lltvshow.com.

Important Medical Information:
EXOMIND is an FDA-cleared treatment for major depressive disorder in adults who have not achieved satisfactory improvement from antidepressant medication during their current episode. Individual results and treatment experiences may vary. Patients should consult a qualified healthcare provider to determine whether treatment is appropriate for them.

Gila Stern
Inside Business Today/ Life+Leisure
+1 312-620-6522

Media gallery